Abstract
ROP in zone I is very difficult to treat. The conventional treatment modality of laser coagulation results in many recurrences and complications. The author describes very elegant how this problem was approached and solved at his hospital in Korea.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327–33.
Kim J, Kim SJ, Chang YS, Park WS. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77–82.
Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, Park WS. Outcomes after laser versus combined laser and Bevacizumab treatment for Type 1 retinopathy of prematurity in zone I. Retina. 2017;37:88–96.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Spandau, U., Kim, S.J. (2019). Combined Laser and Anti-VEGF Treatment for Zone I ROP. In: Pediatric Retinal Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13701-4_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-13701-4_18
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13700-7
Online ISBN: 978-3-030-13701-4
eBook Packages: MedicineMedicine (R0)